PMID- 28411103
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20180403
IS  - 1872-9754 (Electronic)
IS  - 0197-0186 (Linking)
VI  - 107
DP  - 2017 Jul
TI  - Endogenous regeneration: Engineering growth factors for stroke.
PG  - 57-65
LID - S0197-0186(16)30432-6 [pii]
LID - 10.1016/j.neuint.2017.03.024 [doi]
AB  - Despite the efforts in developing therapeutics for stroke, recombinant tissue 
      plasminogen activator (rtPA) remains the only FDA approved drug for ischemic 
      stroke. Regenerative medicine targeting endogenous growth factors has drawn much 
      interest in the clinical field as it provides potential restoration for the 
      damaged brain tissue without being limited by a narrow therapeutic window. To 
      date, most of the translational studies using regenerative medicines have 
      encountered problems and failures. In this review, we discuss the effects of some 
      trophic factors which include of erythropoietin (EPO), brain derived neurotrophic 
      factor (BDNF), granulocyte-colony stimulating factor (G-CSF), vascular 
      endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal 
      growth factor (EGF) and heparin binding epidermal growth factor (HB-EGF) in 
      experimental ischemic stroke models and elaborate the lost in translation of the 
      candidate growth factors from bench to bedside. Several new methodologies have 
      been developed to overcome the caveats in translational studies. This review 
      highlights the latest bioengineering approaches including the controlled release 
      and delivery of growth factors by hydrogel-based scaffolds and the enhancement of 
      half-life and selectivity of growth factors by a novel approach facilitated by 
      glycosaminoglycans.
CI  - Copyright (c) 2017. Published by Elsevier Ltd.
FAU - Chan, Su Jing
AU  - Chan SJ
AD  - Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 
      Charlestown, MA 02129, USA; Institute of Medical Biology, Glycotherapeutics 
      Group, 8A Biomedical Grove, #06-06 Immunos, A*STAR, Singapore 138648, Singapore.
FAU - Love, Christopher
AU  - Love C
AD  - Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 
      Charlestown, MA 02129, USA; Department of Mechanical Engineering, Massachusetts 
      Institute of Technology, Cambridge, MA 02139, USA; Tissue Engineering 
      Laboratories, VA Boston Healthcare System, Boston, MA 02130, USA.
FAU - Spector, Myron
AU  - Spector M
AD  - Tissue Engineering Laboratories, VA Boston Healthcare System, Boston, MA 02130, 
      USA; Department of Orthopaedic Surgery, Brigham & Women's Hospital, Harvard 
      Medical School, Boston, MA 02115, USA; The Harvard-MIT Division of Health 
      Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 
      02139, USA.
FAU - Cool, Simon M
AU  - Cool SM
AD  - Institute of Medical Biology, Glycotherapeutics Group, 8A Biomedical Grove, 
      #06-06 Immunos, A*STAR, Singapore 138648, Singapore.
FAU - Nurcombe, Victor
AU  - Nurcombe V
AD  - Institute of Medical Biology, Glycotherapeutics Group, 8A Biomedical Grove, 
      #06-06 Immunos, A*STAR, Singapore 138648, Singapore. Electronic address: 
      Victor.Nurcombe@imb.a-star.edu.sg.
FAU - Lo, Eng H
AU  - Lo EH
AD  - Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 
      Charlestown, MA 02129, USA; Department of Neurology, Massachusetts General 
      Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: 
      LO@helix.mgh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170412
PL  - England
TA  - Neurochem Int
JT  - Neurochemistry international
JID - 8006959
RN  - 0 (Intercellular Signaling Peptides and Proteins)
SB  - IM
MH  - Animals
MH  - Bioengineering/*methods/trends
MH  - Drug Delivery Systems/*methods/trends
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/*administration & dosage/metabolism
MH  - Regeneration/*drug effects/physiology
MH  - Stroke/*drug therapy/metabolism
EDAT- 2017/04/16 06:00
MHDA- 2018/04/04 06:00
CRDT- 2017/04/16 06:00
PHST- 2016/11/07 00:00 [received]
PHST- 2017/03/30 00:00 [revised]
PHST- 2017/03/31 00:00 [accepted]
PHST- 2017/04/16 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2017/04/16 06:00 [entrez]
AID - S0197-0186(16)30432-6 [pii]
AID - 10.1016/j.neuint.2017.03.024 [doi]
PST - ppublish
SO  - Neurochem Int. 2017 Jul;107:57-65. doi: 10.1016/j.neuint.2017.03.024. Epub 2017 
      Apr 12.